feed,title,long_url,short_url
Benzinga,Nearly 66% Of Patients Respond To Eli Lilly's Mirikizumab In Ulcerative Colitis Study,https://benzinga.com/general/biotech/22/02/25718549/nearly-66-of-patients-respond-to-eli-lillys-mirikizumab-in-ulcerative-colitis-study,https://bit.ly/3LI8rfq
